Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Contemporary Views on the Nature and Clinical Application of Thymus Preparations.

Russian journal of immunology : RJI : official journal of Russian Society of Immunology

Arion VY, Zimina IV, Lopuchin YM.
PMID: 12687070
Russ J Immunol. 1997 Dec;2(3):157-166.

The contemporary views on the clinical application and efficiency of the most well-known peptide preparations isolated from thymus are presented in this review. Among these preparations are thymosins, thymulin, thymopoetin, thymostimulin, thymopentin, thymalin, tactivin, and others. The results of...

Cite
Arion VY, Zimina IV, Lopuchin YM. Contemporary Views on the Nature and Clinical Application of Thymus Preparations. Russ J Immunol. 1997;2(3):157-166
Arion, V. Y., Zimina, I. V., & Lopuchin, Y. M. (1997). Contemporary Views on the Nature and Clinical Application of Thymus Preparations. Russian journal of immunology : RJI : official journal of Russian Society of Immunology, 2(3), 157-166.
Arion, Vitaly Ya., et al. "Contemporary Views on the Nature and Clinical Application of Thymus Preparations." Russian journal of immunology : RJI : official journal of Russian Society of Immunology vol. 2,3 (1997): 157-166.
Arion VY, Zimina IV, Lopuchin YM. Contemporary Views on the Nature and Clinical Application of Thymus Preparations. Russ J Immunol. 1997 Dec;2(3):157-166. PMID: 12687070.
Copy Download .nbib Format: NLM
Relationship between icam-1 serum levels and thymostimulin therapy in patients with liver-cirrhosis associated with hepatocellular-carcinoma.

Oncology reports

Palmieri G, Pirozzi G, Delgaudio E, Ferraiuolo C, Lombardi M, Morabito A, Rea A, Manzo C.
PMID: 21597739
Oncol Rep. 1995 May;2(3):351-5. doi: 10.3892/or.2.3.351.

Intercellular adhesion molecule-1 (ICAM-1), is a cell surface molecule involved in many immunological processes. Recently, ICAM-1 has also been detected as a soluble form in sera of patients affected by different pathologies and often associated with severity of the...

Cite
Palmieri G, Pirozzi G, Delgaudio E, et al. Relationship between icam-1 serum levels and thymostimulin therapy in patients with liver-cirrhosis associated with hepatocellular-carcinoma. Oncol Rep. 1995;2(3):351-5doi: 10.3892/or.2.3.351.
Palmieri, G., Pirozzi, G., Delgaudio, E., Ferraiuolo, C., Lombardi, M., Morabito, A., Rea, A., & Manzo, C. (1995). Relationship between icam-1 serum levels and thymostimulin therapy in patients with liver-cirrhosis associated with hepatocellular-carcinoma. Oncology reports, 2(3), 351-5. https://doi.org/10.3892/or.2.3.351
Palmieri, G, et al. "Relationship between icam-1 serum levels and thymostimulin therapy in patients with liver-cirrhosis associated with hepatocellular-carcinoma." Oncology reports vol. 2,3 (1995): 351-5. doi: https://doi.org/10.3892/or.2.3.351
Palmieri G, Pirozzi G, Delgaudio E, Ferraiuolo C, Lombardi M, Morabito A, Rea A, Manzo C. Relationship between icam-1 serum levels and thymostimulin therapy in patients with liver-cirrhosis associated with hepatocellular-carcinoma. Oncol Rep. 1995 May;2(3):351-5. doi: 10.3892/or.2.3.351. PMID: 21597739.
Copy Download .nbib Format: NLM
Modern Immunotherapy in Clinical Medicine: Present and Future.

Russian journal of immunology : RJI : official journal of Russian Society of Immunology

Nesterova IV.
PMID: 12687147
Russ J Immunol. 1999 Dec;4(4):322-326.

In this manuscript an attempt is made to review the most important information pertinent to the main immunotropic preparations used now in different fields of clinical medicine. Numerous studies have confirmed high clinico-immunological efficiency of natural and synthetic thymus...

Cite
Nesterova IV. Modern Immunotherapy in Clinical Medicine: Present and Future. Russ J Immunol. 1999;4(4):322-326
Nesterova, I. V. (1999). Modern Immunotherapy in Clinical Medicine: Present and Future. Russian journal of immunology : RJI : official journal of Russian Society of Immunology, 4(4), 322-326.
Nesterova, Irina V.. "Modern Immunotherapy in Clinical Medicine: Present and Future." Russian journal of immunology : RJI : official journal of Russian Society of Immunology vol. 4,4 (1999): 322-326.
Nesterova IV. Modern Immunotherapy in Clinical Medicine: Present and Future. Russ J Immunol. 1999 Dec;4(4):322-326. PMID: 12687147.
Copy Download .nbib Format: NLM
Could thymostimulin prevent hepatocellular carcinoma occurrence in patients with liver cirrhosis?.

Oncology reports

Palmieri G, Biondi E, Morabito A, Rea A, Bianco A.
PMID: 21594429
Oncol Rep. 1996 Jul;3(4):655-6. doi: 10.3892/or.3.4.655.

On the basis of a possible pathogenetic role of immunodepression in the development of hepatocellular carcinoma in patients with chronic hepatitis B/C viral infection and liver cirrhosis, we treated 34 liver cirrhosis patients (M/F 24/10; age: 14 pts less...

Cite
Palmieri G, Biondi E, Morabito A, et al. Could thymostimulin prevent hepatocellular carcinoma occurrence in patients with liver cirrhosis?. Oncol Rep. 1996;3(4):655-6doi: 10.3892/or.3.4.655.
Palmieri, G., Biondi, E., Morabito, A., Rea, A., & Bianco, A. (1996). Could thymostimulin prevent hepatocellular carcinoma occurrence in patients with liver cirrhosis?. Oncology reports, 3(4), 655-6. https://doi.org/10.3892/or.3.4.655
Palmieri, G, et al. "Could thymostimulin prevent hepatocellular carcinoma occurrence in patients with liver cirrhosis?." Oncology reports vol. 3,4 (1996): 655-6. doi: https://doi.org/10.3892/or.3.4.655
Palmieri G, Biondi E, Morabito A, Rea A, Bianco A. Could thymostimulin prevent hepatocellular carcinoma occurrence in patients with liver cirrhosis?. Oncol Rep. 1996 Jul;3(4):655-6. doi: 10.3892/or.3.4.655. PMID: 21594429.
Copy Download .nbib Format: NLM
Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis.

International journal of oncology

Palmieri G, Biondi E, Morabito A, Rea A, Gravina A, Bianco A.
PMID: 21544434
Int J Oncol. 1996 Apr;8(4):827-32. doi: 10.3892/ijo.8.4.827.

Hepatocellular carcinoma (HCC) on liver cirrhosis (LC) is a neoplasm with a poor prognosis. Only 10-36% of patients have resectable tumors at presentation, systemic chemotherapy is seldom useful and loco-regional treatments are feasible only in selected cases. On the...

Cite
Palmieri G, Biondi E, Morabito A, et al. Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis. Int J Oncol. 1996;8(4):827-32doi: 10.3892/ijo.8.4.827.
Palmieri, G., Biondi, E., Morabito, A., Rea, A., Gravina, A., & Bianco, A. (1996). Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis. International journal of oncology, 8(4), 827-32. https://doi.org/10.3892/ijo.8.4.827
Palmieri, G, et al. "Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis." International journal of oncology vol. 8,4 (1996): 827-32. doi: https://doi.org/10.3892/ijo.8.4.827
Palmieri G, Biondi E, Morabito A, Rea A, Gravina A, Bianco A. Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis. Int J Oncol. 1996 Apr;8(4):827-32. doi: 10.3892/ijo.8.4.827. PMID: 21544434.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries